Form 4: X4 Pharmaceuticals Chief Scientific Officer Sells Shares to Cover Tax Obligations

Arthur Taveras, Chief Scientific Officer of X4 Pharmaceuticals, sold 14,235 shares of common stock on March 11, 2024, to cover personal income tax obligations related to a restricted stock unit award.

Summary

• On March 11, 2024, Arthur Taveras, the Chief Scientific Officer of X4 Pharmaceuticals, sold 14,235 shares of the company's common stock.
• The sale was executed at a weighted average price of $0.8818 per share, with individual transactions ranging from $0.863 to $0.9112.
• The purpose of the sale was to cover personal income tax obligations arising from the settlement of a restricted stock unit award.
• Following the transaction, Taveras directly owns 234,301 shares of X4 Pharmaceuticals.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 24, 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction to cover tax obligations, executed under a pre-existing trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Form 4 filings are a routine part of the financial markets, providing transparency into the transactions of company insiders. This particular filing indicates a sale of shares by a high-ranking executive to cover tax obligations, which is a common occurrence.

Stakeholder Impact

• The sale of shares by an insider could be perceived negatively by some shareholders, although the context of covering tax obligations under a pre-arranged plan mitigates this concern.

Key Dates